Literature DB >> 23150340

Interactions between the tumor suppressor p53 and immune responses.

Daniel Menendez1, Maria Shatz, Michael A Resnick.   

Abstract

PURPOSE OF REVIEW: The p53 tumor suppressor is a master regulator of antitumor defenses through its control of growth arrest, senescence and apoptosis. In recent years, p53 regulation was found to extend to a variety of biological processes including autophagy, fertility, metabolism and immune responses. Here, we focus on the role of p53 in the immune system. We explore the relationship between p53 and the innate immune response with particular emphasis on the Toll-like receptor (TLR) pathway and implications for cancer therapy. RECENT
FINDINGS: Numerous studies have shown that the immune system, especially innate immunity, has a critical role in tumor development. It appears that p53 can influence innate immune responses as part of its tumor suppressor activities and recent work suggests that the complete set of innate immune TLR genes are responsive to chromosomal stress and the transcriptional network regulated by p53. Activation of p53 by common antitumor agents results in p53 dependent regulation of expression of most TLR genes in human primary and cancer cell lines, resulting in modulation of TLR downstream responses to cognate ligands. In addition several tumor-associated p53 mutants can also affect TLR gene expression. These observations together with the discovery of other immune-related p53 target genes provide new insights into the relationship between p53 and immunity and suggest approaches that might be useful in cancer therapies.
SUMMARY: The tumor suppressor p53 can modulate innate immune gene responses in response to factors that can activate p53. This is expected to provide new opportunities in cancer diagnosis and in chemotherapeutic strategies that employ specific TLR agonists or antagonists that target the TLR pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23150340     DOI: 10.1097/CCO.0b013e32835b6386

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  55 in total

1.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.

Authors:  Steven A Roberts; Michael S Lawrence; Leszek J Klimczak; Sara A Grimm; David Fargo; Petar Stojanov; Adam Kiezun; Gregory V Kryukov; Scott L Carter; Gordon Saksena; Shawn Harris; Ruchir R Shah; Michael A Resnick; Gad Getz; Dmitry A Gordenin
Journal:  Nat Genet       Date:  2013-07-14       Impact factor: 38.330

2.  Pleiotropic Role of p53 in Injury and Liver Regeneration after Acetaminophen Overdose.

Authors:  Prachi Borude; Bharat Bhushan; Sumedha Gunewardena; Jephte Akakpo; Hartmut Jaeschke; Udayan Apte
Journal:  Am J Pathol       Date:  2018-04-11       Impact factor: 4.307

3.  The BM2 protein of influenza B virus interacts with p53 and inhibits its transcriptional and apoptotic activities.

Authors:  H Zhang; H Yu; J Wang; M Zhang; X Wang; W Ahmad; M Duan; Z Guan
Journal:  Mol Cell Biochem       Date:  2015-02-11       Impact factor: 3.396

4.  Potential functional variants in SMC2 and TP53 in the AURORA pathway genes and risk of pancreatic cancer.

Authors:  Yun Feng; Hongliang Liu; Bensong Duan; Zhensheng Liu; James Abbruzzese; Kyle M Walsh; Xuefeng Zhang; Qingyi Wei
Journal:  Carcinogenesis       Date:  2019-06-10       Impact factor: 4.944

5.  Lung Cancer Subtypes Generate Unique Immune Responses.

Authors:  Stephanie E Busch; Mark L Hanke; Julia Kargl; Heather E Metz; David MacPherson; A McGarry Houghton
Journal:  J Immunol       Date:  2016-10-31       Impact factor: 5.422

Review 6.  Mechanisms of hepatocarcinogenesis in chronic hepatitis C.

Authors:  Jonathan K Mitchell; David R McGivern
Journal:  Hepat Oncol       Date:  2014-09-09

Review 7.  Key mechanisms involved in ionizing radiation-induced systemic effects. A current review.

Authors:  Ifigeneia V Mavragani; Danae A Laskaratou; Benjamin Frey; Serge M Candéias; Udo S Gaipl; Katalin Lumniczky; Alexandros G Georgakilas
Journal:  Toxicol Res (Camb)       Date:  2015-08-11       Impact factor: 3.524

Review 8.  Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Authors:  A R M Ruhul Amin; Phillip A Karpowicz; Thomas E Carey; Jack Arbiser; Rita Nahta; Zhuo G Chen; Jin-Tang Dong; Omer Kucuk; Gazala N Khan; Gloria S Huang; Shijun Mi; Ho-Young Lee; Joerg Reichrath; Kanya Honoki; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Alan Bilsland; Dong M Shin
Journal:  Semin Cancer Biol       Date:  2015-03-06       Impact factor: 15.707

9.  TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer.

Authors:  Harsimar B Kaur; Jiayun Lu; Liana B Guedes; Laneisha Maldonado; Logan Reitz; John R Barber; Angelo M De Marzo; Scott A Tomlins; Karen S Sfanos; Mario Eisenberger; Edward M Schaeffer; Corinne E Joshu; Tamara L Lotan
Journal:  Hum Pathol       Date:  2019-03-06       Impact factor: 3.466

Review 10.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.